Assorted News from the Last Week: CAC2 Supporting Organization Member Syndax Pharmaceuticals announced that the Food and Drug Administration approved revumenib, a menin inhibitor, for
When I first heard about the Coalition Against Childhood Cancer (CAC2), I remember thinking — this is what our community has been waiting for. A
Assorted News from the Last Week: This edition of the CAC2 blog post addresses how childhood cancer affects the academic success of school-aged siblings. Iopofosine-131
By CAC2 Staffer Bethany Lieberman This is the second blog in a two-part series. This post addresses how childhood cancer affects the academic success of
Assorted News from the Last Week: South African authorities have suspended eight pupils linked to a case of alleged bullying of a childhood cancer patient
Assorted News from the Last Week: U.S. policy changes mean Canadian children with cancer are losing access to clinical trials. Sensitisation, early detection: The lifeline
Assorted News from the Last Week: This edition of the CAC2 blog post addresses the needs of children impacted by an education interruption due to
By CAC2 Staffer Bethany Lieberman This is the first blog in a two-part series. This post addresses the needs of children impacted by an education
Assorted News from the Last Week: Following an Executive Order by President Trump, the U.S. Department of Health and Human Services announced a doubling of
Assorted News from the Last Week: Childhood cancer cases are on the rise across the EU. Zebrafish models offer fast, effective guidance for personalized therapies
